Iambic Therapeutics · Company profile
Iambic Therapeutics · 美国 · AI, models, and data
Registered focus: AI药物发现、小分子设计. Focus is directory metadata; inspect the sources and project evidence below to assess specific capabilities.
Aliases: Iambic
Public reviewed developments
Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。
Iambic 与 AbbVie 宣布 AI 药物发现合作
Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。
Iambic 与拜耳合作推进 AI 小分子发现
Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。
Collaboration, licensing, and acquisition timeline
Iambic 与 AbbVie 宣布 AI 药物发现合作
Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。
Iambic 与拜耳合作推进 AI 小分子发现
Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items
据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。
These are drawn from the latest 3 reviewed developments. A collaboration, model performance, experimental results, and clinical progress each require their own evidence.
Public source records
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic official newsroom · Indexed industry source record · Source published: Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)
In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intr
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Iambic official newsroom · Indexed industry source record · Source published: Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)
− Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Iambic official newsroom · Indexed industry source record · Source published: Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)
Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse data
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · Indexed industry source record · Source published: Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · Indexed industry source record · Source published: Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Verified official and subscription sources
- Iambic official newsroom · Collection enabled · Last successful collection Fri Oct 09 2026 07:09:11 GMT+0000 (Coordinated Universal Time)
Source verification and ongoing collection are shown separately. Indexed source records do not automatically become reviewed events.
Reader guides: from sources to conclusions
Compare models by task and follow collaborations through evidence. Each guide includes original sources and a review date.
How should we compare virtual cells, AI models, and companies?
Compare single-cell models, structure prediction, and protein design by inputs, outputs, tasks, and validation conditions. Distinguish model papers from company capabilities.
Reader guide · updated 2026-10-08
AI drug discovery collaboration timelines: from announcements to evidence
Use real official announcements to distinguish partners, upfront payments, conditional milestones, and R&D progress, and build a traceable collaboration timeline.
Reader guide · updated 2026-10-08
How to read weekly AI drug discovery updates: companies, research, and coverage gaps
Build a weekly reading routine, distinguish announcements, papers, and clinical results, and understand this site’s weekly indexing window, denominators, and source coverage.
Reader guide · updated 2026-10-08